CHARLOTTE FERRELL SMITH
In 2012, the FDA approved the combination of pertuzumab with trastuzumab and docetaxel as the first dual anti-HER2 regimen for the treatment of patients with HER2-positive metastatic breast cancer. Then, in December 2017, the agency granted regular approval to pertuzumab plus trastuzumab and chemothe...
cancer.A secondary endpoint of the EMILIA study was time to symptom worsening (time from randomization to the first documentation of a ≥ 5-point decrease from baseline) as measured by the Trial Outcome Index Physical/Functional/Breast (TOI-PFB) subset of the Functional Assessment of Cancer ...
tucatinib instead. For a patient who has active or previously treated CNS [central nervous system] metastases, I would likely go for tucatinib as the preferred regimen first, then switch to T-DXd at the time of progression. It’s shared decision-making between myself and the patient when we...
(Rather than waiting for certain things to come your way or opportunities to fall into your lap you have to be a go-getter. At the same time it’s important to not look too desperate and be patient with goals. Some goals require less work than others.) Keep A Quotes Journal. (Recordi...
‘It’s not if I get cancer, it’s when I get cancer.’ This simple yet profound statement summarizes the experience of a patient who has tested positive for a BReast CAncer (BRCA) genetic mutation but has not been diagnosed with cancer. Individuals who test positive for a harmful BRCA ...
We assessed health-related quality of life (symptoms of therapy/patient functioning/global health status), in APHINITY (pertuzumab/placebo, trastuzumab, and chemotherapy as adjuvant HER2-positive early breast cancer therapy). Patients received 1 year/18
This cohort study uses pooled patient-level data from the SWOG Cancer Research Network to assess whether positive treatment effects are associated with
Figure 1. Generation of a lung cancer PDX model with NRG1 fusion. (A) Patient history revealing major therapeutic interventions, results of molecular diagnostics, and time points of PDX establishment. (B, C) Growth curves of the first five serial passages revealed continuous growth of the xenogr...
SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering ...